amantadine has been researched along with Brain Injuries in 68 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The following case report describes a patient developing neuroleptic malignant syndrome (NMS) secondary to the use of haloperidol given to control the patient's agitation." | 7.70 | Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. ( Guin-Renfroe, S; Meythaler, JM; Wilkinson, R, 1999) |
| "The results of our study will help to systematically assess the clinical utility of amantadine for treatment of persisting coma in non-traumatic brain injury." | 5.69 | Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES). ( Adeyemi, K; Blum, C; Bösel, R; Brendel, B; Feil, K; Häberle, HA; Haug, I; Hofmann, A; Martus, P; Mengel, A; Rattay, TW; Riessen, R; Schwarz, P; Single, C; Siokas, V; Zago, M; Ziemann, U, 2023) |
| "Among them, depression is a common psychiatric symptom, and links to poorer recovery." | 5.42 | Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. ( Chen, Y; Duanmu, W; Feng, H; Fu, C; Ge, H; Hu, R; Liu, X; Sui, J; Tan, L; Tang, J, 2015) |
| "This comprehensive review discusses clinical studies of patients following brain injuries (traumatic, acquired, or stroke), who have been treated with amantadine or memantine." | 5.05 | Amantadine and memantine: a comprehensive review for acquired brain injury. ( Ma, HM; Zafonte, RD, 2020) |
| "Literature was accessed through MEDLINE (1950-August 2007) using the MeSH terms amantadine, brain injuries, cognition, and arousal." | 4.84 | Amantadine enhancement of arousal and cognition after traumatic brain injury. ( Mauro, LS; Ohlinger, MJ; Sawyer, E, 2008) |
| "We pooled individual patient data of five single-centre observational studies to determine the effect of amantadine treatment among patients with ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, community-acquired bacterial meningitis and status epilepticus, admitted between January 2012 and December 2015 and ventilated ≥7 days." | 4.12 | Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury. ( Balk, S; Gerner, ST; Giede-Jeppe, A; Huttner, HB; Jäger, J; Kallmünzer, B; Kuramatsu, JB; Madzar, D; Mueller, T; Rühl, L; Schwab, S; Sembill, JA; Sprügel, MI, 2022) |
| "We propose that a combination of levetiracetam and amantadine may provide neuroprotective and neurorestorative properties when administered during a period of hyperpyrexia accompanied by any form of mental status changes, particularly if there is a decline in Glasgow Coma Score." | 3.85 | Preserving brain function in a comatose patient with septic hyperpyrexia (41.6 °C): a case report. ( Akinyemi, A; Michel, G; Sanchez-Gonzalez, MA; Sterkel, S, 2017) |
| "The use of the atypical neuroleptic medication, risperidone, may be considered as part of the armamentarium available to physicians treating restlessness in severe brain injuries." | 3.72 | Risperidone treatment of motor restlessness following anoxic brain injury. ( Collins, L; Silver, BV; Zidek, KA, 2003) |
| " The following case report describes a patient developing neuroleptic malignant syndrome (NMS) secondary to the use of haloperidol given to control the patient's agitation." | 3.70 | Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. ( Guin-Renfroe, S; Meythaler, JM; Wilkinson, R, 1999) |
| " Case 1 is a description of the subjective experience of a patient with acute orofacial dystonia from promethazine." | 3.66 | Case vignettes of movement disorders. ( Yung, CY, 1983) |
| "Amantadine has been shown to promote the rate of neurologic recovery for patients with traumatic disorders of consciousness when administered between 4 and 16 weeks, as demonstrated by a well-designed randomized control trial." | 3.54 | Pharmacology in Treatment of Patients with Disorders of Consciousness. ( Marino, MH, 2024) |
| " Based on the preliminary data, higher dosing may be considered in the setting of brain injury." | 2.75 | Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. ( Bean, J; McMahon, MA; Michaud, LJ; Vargus-Adams, JN; Vinks, AA, 2010) |
| " Medication dosage was increased over 4 weeks, weaned over 2 weeks, and then discontinued." | 2.72 | Dopamine agonist therapy in low-response children following traumatic brain injury. ( Blackman, JA; Buck, ML; Conaway, MR; Gurka, MJ; Mabry, JL; Patrick, PD, 2006) |
| "Optimizing the recovery from coma is a priority in seeking to improve patients' functional outcomes." | 2.50 | Therapeutic options to enhance coma arousal after traumatic brain injury: state of the art of current treatments to improve coma recovery. ( Cossu, G, 2014) |
| " Notably, drug dosage and the measure chosen to assess outcome influenced the probability of finding a treatment benefit." | 2.45 | Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: a meta-analysis. ( Mathias, JL; Vink, R; Wheaton, P, 2009) |
| " Dosage use and side effect profiles were consistent with expected norms." | 2.44 | Amantadine treatment following traumatic brain injury in children. ( Williams, SE, 2007) |
| "Among them, depression is a common psychiatric symptom, and links to poorer recovery." | 1.42 | Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats. ( Chen, Y; Duanmu, W; Feng, H; Fu, C; Ge, H; Hu, R; Liu, X; Sui, J; Tan, L; Tang, J, 2015) |
| " Amantadine or saline control was administered intraperitoneally, starting at 1 h after TBI followed by dosing three times daily for 16 consecutive days at 15, 45, and 135 mg/kg/day." | 1.40 | Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats. ( Huang, XJ; Lyeth, BG; Nguyen, JT; Van, KC; Wang, T; Went, GT, 2014) |
| "As amantadine is a frequently employed drug in brain injury rehabilitation, with known effects on fatigue and motor processing speed, this study examined the effect of amantadine on the sleep-wake behaviour of patients with brain injury undergoing rehabilitation." | 1.35 | Effect of amantadine on the sleep-wake cycle of an inpatient with brain injury. ( Al-Adawi, S; Burke, DT; Dorvlo, AS; Hoaglin, H; Vesali, F, 2009) |
| "Neurobehavioural sequelae of traumatic brain injuries require an appropriate/effective pharmacological response in that they represent an important cause of disability." | 1.35 | Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury. ( Lombardi, F, 2008) |
| "Amantadine is a reasonable option for improving cognition and reducing agitation following a TBI but confirmatory evidence of the efficacy the drug is necessary." | 1.33 | Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? ( Leone, H; Polsonetti, BW, 2005) |
| "Amantadine is a well tolerated medication when it is used in pediatric patients with traumatic brain injury." | 1.32 | Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study. ( Green, LB; Hornyak, JE; Hurvitz, EA, 2004) |
| " This long range study demonstrates, through multiple varied dosing schedules, a trade off between the benefits and side effects of dopaminergic therapy, with implications for a larger brain injury population." | 1.30 | Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. ( Burke, DT; Calvanio, R; Fitzpatrick, M; Karli, DC; Kim, HJ; Lepak, P; Macneil, M; Pesez, K; Temple, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.35) | 18.7374 |
| 1990's | 10 (14.71) | 18.2507 |
| 2000's | 25 (36.76) | 29.6817 |
| 2010's | 20 (29.41) | 24.3611 |
| 2020's | 8 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| FitzGerald, A | 1 |
| Main, L | 1 |
| Duff, U | 1 |
| Foggo, J | 1 |
| Rowney, F | 1 |
| Haire, N | 1 |
| McLean, R | 1 |
| Rühl, L | 1 |
| Kuramatsu, JB | 1 |
| Sembill, JA | 1 |
| Kallmünzer, B | 1 |
| Madzar, D | 1 |
| Gerner, ST | 1 |
| Giede-Jeppe, A | 1 |
| Balk, S | 1 |
| Mueller, T | 1 |
| Jäger, J | 1 |
| Schwab, S | 1 |
| Huttner, HB | 1 |
| Sprügel, MI | 1 |
| Hofmann, A | 1 |
| Blum, C | 1 |
| Single, C | 1 |
| Adeyemi, K | 1 |
| Schwarz, P | 1 |
| Siokas, V | 1 |
| Rattay, TW | 1 |
| Häberle, HA | 1 |
| Riessen, R | 1 |
| Brendel, B | 1 |
| Haug, I | 1 |
| Bösel, R | 1 |
| Zago, M | 1 |
| Martus, P | 1 |
| Ziemann, U | 1 |
| Mengel, A | 1 |
| Feil, K | 1 |
| Marino, MH | 1 |
| Lee, S | 1 |
| Lee, HH | 1 |
| Lee, Y | 1 |
| Lee, J | 1 |
| Ma, HM | 1 |
| Zafonte, RD | 4 |
| Spauwen, P | 1 |
| Ter Mors, B | 1 |
| van Harten, P | 1 |
| Domensino, AF | 1 |
| Ponds, R | 1 |
| van Heugten, C | 1 |
| Shimia, M | 1 |
| Iranmehr, A | 1 |
| Valizadeh, A | 1 |
| Mirzaei, F | 1 |
| Namvar, M | 1 |
| Rafiei, E | 1 |
| Rahimi, A | 1 |
| Khadivi, A | 1 |
| Aeinfar, K | 1 |
| Wang, T | 1 |
| Huang, XJ | 1 |
| Van, KC | 1 |
| Went, GT | 1 |
| Nguyen, JT | 1 |
| Lyeth, BG | 1 |
| Whyte, J | 4 |
| Nordenbo, AM | 1 |
| Kalmar, K | 3 |
| Merges, B | 1 |
| Bagiella, E | 2 |
| Chang, H | 1 |
| Yablon, S | 1 |
| Cho, S | 2 |
| Hammond, F | 1 |
| Khademi, A | 2 |
| Giacino, J | 2 |
| Cossu, G | 1 |
| Huang, EY | 1 |
| Tsui, PF | 1 |
| Kuo, TT | 1 |
| Tsai, JJ | 1 |
| Chou, YC | 1 |
| Ma, HI | 1 |
| Chiang, YH | 1 |
| Chen, YH | 1 |
| McQueen, R | 1 |
| O'Shanick, GJ | 1 |
| Tan, L | 1 |
| Ge, H | 1 |
| Tang, J | 2 |
| Fu, C | 1 |
| Duanmu, W | 1 |
| Chen, Y | 1 |
| Hu, R | 1 |
| Sui, J | 1 |
| Liu, X | 1 |
| Feng, H | 1 |
| Gwynette, MF | 1 |
| Beck, B | 1 |
| VandenBerg, A | 1 |
| Stocking, N | 1 |
| Spritzer, SD | 1 |
| Kinney, CL | 1 |
| Condie, J | 1 |
| Wellik, KE | 1 |
| Hoffman-Snyder, CR | 1 |
| Wingerchuk, DM | 1 |
| Demaerschalk, BM | 1 |
| Hammond, FM | 2 |
| Sherer, M | 2 |
| Malec, JF | 1 |
| Whitney, M | 1 |
| Bell, K | 1 |
| Dikmen, S | 1 |
| Bogner, J | 1 |
| Mysiw, J | 1 |
| Pershad, R | 1 |
| Luauté, J | 2 |
| Plantier, D | 2 |
| Wiart, L | 1 |
| Tell, L | 1 |
| Sterkel, S | 1 |
| Akinyemi, A | 1 |
| Sanchez-Gonzalez, MA | 1 |
| Michel, G | 1 |
| Titova, E | 1 |
| Ostrowski, RP | 1 |
| Zhang, JH | 1 |
| McMahon, MA | 2 |
| Vargus-Adams, JN | 2 |
| Michaud, LJ | 2 |
| Bean, J | 2 |
| Al-Adawi, S | 1 |
| Hoaglin, H | 1 |
| Vesali, F | 1 |
| Dorvlo, AS | 1 |
| Burke, DT | 2 |
| Wheaton, P | 1 |
| Mathias, JL | 1 |
| Vink, R | 1 |
| Vinks, AA | 1 |
| Meyer, MJ | 1 |
| Megyesi, J | 1 |
| Meythaler, J | 1 |
| Murie-Fernandez, M | 1 |
| Aubut, JA | 1 |
| Foley, N | 1 |
| Salter, K | 1 |
| Bayley, M | 1 |
| Marshall, S | 1 |
| Teasell, R | 1 |
| Meehan, WP | 1 |
| Bales, JW | 1 |
| Yan, HQ | 1 |
| Ma, X | 1 |
| Li, Y | 1 |
| Samarasinghe, R | 1 |
| Dixon, CE | 1 |
| Cheliapina, MV | 1 |
| Sharova, EV | 1 |
| Zaĭtsev, OS | 1 |
| Giacino, JT | 1 |
| Childs, N | 2 |
| Eifert, B | 2 |
| Long, D | 2 |
| Katz, DI | 1 |
| Yablon, SA | 1 |
| Luther, M | 1 |
| Nordenbo, A | 1 |
| Novak, P | 2 |
| Mercer, W | 2 |
| Maurer-Karattup, P | 1 |
| Mukherjee, D | 1 |
| Patil, CG | 1 |
| Palestrant, D | 1 |
| Dlouhy, BJ | 1 |
| Rao, RC | 1 |
| Fleminger, S | 2 |
| Greenwood, RJ | 2 |
| Oliver, DL | 2 |
| Silver, BV | 1 |
| Collins, L | 1 |
| Zidek, KA | 1 |
| Patrick, PD | 2 |
| Buck, ML | 2 |
| Conaway, MR | 2 |
| Blackman, JA | 2 |
| Green, LB | 1 |
| Hornyak, JE | 1 |
| Hurvitz, EA | 1 |
| Arciniegas, DB | 1 |
| Frey, KL | 1 |
| Anderson, CA | 1 |
| Brousseau, KM | 1 |
| Harris, SN | 1 |
| Katz, D | 1 |
| DiPasquale, MC | 1 |
| Polansky, M | 1 |
| Maurer, P | 1 |
| Wu, TS | 1 |
| Garmel, GM | 1 |
| Leone, H | 1 |
| Polsonetti, BW | 1 |
| Napolitano, E | 1 |
| Elovic, EP | 1 |
| Qureshi, AI | 1 |
| Hughes, S | 1 |
| Colantonio, A | 1 |
| Santaguida, PL | 1 |
| Paton, T | 1 |
| Mabry, JL | 1 |
| Gurka, MJ | 1 |
| Rao, V | 1 |
| Handel, S | 1 |
| Vaishnavi, S | 1 |
| Keach, S | 1 |
| Robbins, B | 1 |
| Spiro, J | 1 |
| Ward, J | 1 |
| Berlin, F | 1 |
| Barrett, AM | 1 |
| Levy, CE | 1 |
| Gonzalez Rothi, LJ | 1 |
| Williams, SE | 1 |
| Sawyer, E | 1 |
| Mauro, LS | 1 |
| Ohlinger, MJ | 1 |
| Lombardi, F | 1 |
| Yung, CY | 1 |
| Rohde, H | 1 |
| Edby, K | 1 |
| Larsson, J | 1 |
| Eek, M | 1 |
| von Wendt, L | 1 |
| Ostergård, B | 1 |
| Hartshorne, NJ | 1 |
| Harruff, RC | 1 |
| Logan, BK | 1 |
| Kraus, MF | 2 |
| Maki, PM | 1 |
| Maki, P | 1 |
| Watanabe, T | 1 |
| Mann, NR | 1 |
| Karli, DC | 1 |
| Kim, HJ | 1 |
| Calvanio, R | 1 |
| Fitzpatrick, M | 1 |
| Temple, D | 1 |
| Macneil, M | 1 |
| Pesez, K | 1 |
| Lepak, P | 1 |
| Schneider, WN | 1 |
| Drew-Cates, J | 1 |
| Wong, TM | 1 |
| Dombovy, ML | 1 |
| Wilkinson, R | 1 |
| Meythaler, JM | 2 |
| Guin-Renfroe, S | 1 |
| Lexell, J | 1 |
| Cullen, N | 1 |
| Rosati, DL | 1 |
| Brunner, RC | 1 |
| Johnson, A | 1 |
| Novack, TA | 1 |
| Andersson, S | 1 |
| Berstad, J | 1 |
| Finset, A | 1 |
| Grimsmo, J | 1 |
| Hinkle, JL | 1 |
| Gualtieri, T | 1 |
| Chandler, M | 1 |
| Coons, TB | 1 |
| Brown, LT | 1 |
| Paini, GP | 1 |
| Passoni, M | 1 |
| Borromei, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study[NCT04427241] | Phase 4 | 12 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | ||
| The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU[NCT06052787] | Phase 3 | 150 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | ||
| A Multi-Center, Parallel-Group, Randomized, Double-Blind, Placebo-Controlled Trial of Amantadine Hydrochloride in the Treatment of Chronic Traumatic Brain Injury Irritability and Aggression: A Replication Study[NCT00779324] | 168 participants (Actual) | Interventional | 2009-08-31 | Completed | |||
| Effectiveness of Sensory Stimulation for Person in a Coma or Persistent Vegetative State After Traumatic Brain Injury[NCT02629588] | 9 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Transcranial LED Therapy for the Treatment of Chronic Mild Traumatic Brain Injury[NCT02383472] | 53 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Safety and Efficacy of Transcranial Direct Current Stimulation in Pediatric Disorders of Consciousness[NCT05929274] | 10 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| A Multicenter Prospective Randomized Controlled Trial of the Effectiveness of Amantadine Hydrochloride in Promoting Recovery of Function Following Severe Traumatic Brain Injury[NCT00970944] | Phase 2/Phase 3 | 184 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -4 |
| Placebo | -4 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -5 |
| Placebo | -4 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -3 |
| Placebo | -2 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | -3 |
| Placebo | -2 |
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 28 Days
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | 3.00 |
| Placebo | 3.00 |
Study physician's impression of change since study onset. Clinicians Global Impressions of Change (CGI) is a sensitive, standardized tool to assess psychopharmacologic treatment response completed by the study physician. The Global Improvement (GI) CGI subscale documented the clinician's impression of change. The GI uses a 7-point scale to assess beneficial and negative effects. Low GI values (1 -3) indicate improvement; higher values (4-7) represent worsening. (NCT00779324)
Timeframe: 60 days
| Intervention | score on a scale (Median) |
|---|---|
| Amantadine | 3.00 |
| Placebo | 3.00 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 66.3 |
| Placebo | 66.7 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 28
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 51.3 |
| Placebo | 40.5 |
The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: Day 60
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 60.5 |
| Placebo | 48.8 |
As described above for the primary measure, assessed as a secondary measure at Day 60. The Neuropsychiatric Inventory (NPI) is a 40-item rating scale developed to assess 12 behavioral domains. Only the NPI-Irritability (NPI-I) domain was used for this study. NPI-I measures irritability with items including: bad temper, rapid mood changes, sudden anger, impatience, crankiness, argumentative. The rater selects the frequency (1-3) and severity (1-4) of the most problematic of these behavioral aspect(s) over the preceding month. The NPI score is the product of the frequency and severity for the NPI most problematic item score. The primary outcome measure was the proportion of participants with greater than two-point increase on the Neuropsychiatric Inventory Irritability domain. The total range is 1 (least irritability) - 12 (worst irritability). (NCT00779324)
Timeframe: 60 days
| Intervention | percentage of participants NPI improve>2 (Number) |
|---|---|
| Amantadine | 74.7 |
| Placebo | 68.3 |
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs color-word interferences, made up of color naming, word reading, and inhibition, is measured in seconds, a smaller number represents a better outcome. Participants were given 90 seconds to complete color naming and word reading and 180 seconds to complete inhibition. D-KEFs trail making test, made up of number sequencing, letter sequencing, and number-letter sequencing, is measured in seconds, a faster speed (lower number) represents a better outcome. Participants were given 150 seconds to complete number and letter sequencing and 240 seconds to complete number-letter sequencing. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Seconds (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D-KEFs Color Naming - 3 Weeks | D-KEFs Color Naming - 6 Weeks | D-KEFs Word Reading - 3 Weeks | D-KEFs Word Reading - 6 Weeks | D-KEFs Inhibition - 3 Weeks | D-KEFs Inhibition - 6 Weeks | D-KEFs Number Sequencing - 3 weeks | D-KEFs Letter Sequencing- 3 weeks | D-KEFs Number-Letter Sequencing- 3 weeks | D-KEFs Number Sequencing - 6 weeks | D-KEFs Letter Sequencing- 6 weeks | D-KEFs Number-Letter Sequencing- 6 weeks | |
| MedX Health Console Model 1100 | 3.27 | 3.76 | 0.95 | 1.71 | 7.64 | 32.62 | -24.45 | -28.41 | 8.00 | 11.33 | 6.86 | 12.95 |
| MedX Health Console Model 1100-placebo | 4.76 | 4.07 | 4.07 | 3.44 | 4.48 | 31.59 | -21.17 | -19.51 | 21.93 | 6.89 | 10.59 | 19.81 |
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs Verbal Fluency Test, made up of letter fluency and category fluency, is measured by number of responses, a larger number represents a better outcome. Participants were given 60 seconds to complete each fluency test. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Correct responses (Mean) | |||
|---|---|---|---|---|
| D-KEFs Verbal Fluency- letters 3 weeks | D-KEFs Verbal Fluency- letters 6 weeks | D-KEFs Verbal Fluency- category 3 weeks | D-KEFs Verbal Fluency- category 6 weeks | |
| MedX Health Console Model 1100 | -3.45 | -6.71 | -1.14 | -1.62 |
| MedX Health Console Model 1100-placebo | -6.10 | -9.89 | -0.03 | -2.00 |
The primary outcome is mean difference on composite scores of Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) between entry into the study and completion of treatment (visit 18, week 6) for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 6 week scores. There are 5 composite scores on the ImPACT test; verbal memory, visual memory, visual motor speed, reaction time, and symptom score. The ranges for these subscales are as follows: verbal memory and visual memory: 0-100, visual motor speed: 0-60, reaction time: 0-1.0, and symptom score: 0-132. A higher verbal memory, visual memory, and visual motor speed represent a better outcome, while a lower reaction time and lower symptom score represent a better outcome. (NCT02383472)
Timeframe: From baseline to 6 weeks
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Verbal Memory | Visual Memory | Visual Motor Speed | Reaction Time | Symptom Score | |
| MedX Health Console Model 1100 | -0.9 | 3.52 | -2.04 | -0.001 | 10.14 |
| MedX Health Console Model 1100-placebo | -5.78 | -7.26 | -5.15 | 0.030 | 11.44 |
"This measure indicates the mean difference in total cognitive symptom scores between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 weeks scores. The total cognitive symptom scored is a sum of 7 symptom scores from the PCSS; feeling slowed down, feeling like in a fog, don't feel right, difficulty concentrating, difficulty remembering, fatigue or low energy, and confusion. The severity of these symptoms are scored 0-6, 0=none, 6=severe. The range for the total cognitive symptom score is 0-42, a lower score represents a better outcome." (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Sx Score - 3 Weeks | Cognitive Sx Score - 6 Weeks | |
| MedX Health Console Model 1100 | 3.95 | 4.00 |
| MedX Health Console Model 1100-placebo | 1.31 | 5.00 |
This measure indicates the mean differences in total post concussion symptom score (PCSS) between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. The PCSS is a sum of severity scores from 0-6 (0=none, 6=severe) for 22 individual symptoms, like headache, neck pain, or drowsiness. The range for the PCSS is 0-132, a lower score represents a better outcome. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| PCSS Total Score - 3 Weeks | PCSS Total score - 6 Weeks | |
| MedX Health Console Model 1100 | 9.41 | 7.86 |
| MedX Health Console Model 1100-placebo | 7.03 | 14.63 |
"Measure of function after traumatic brain injury (TBI) intended to measure function from coma to community. Minimum score= 0; Maximum score= 29 (High scores are indicative of greater degree of disability)." (NCT00970944)
Timeframe: Randomization and weekly for 6 weeks. The primary study endpoint was week 4 and drug washout was week 6.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 4 (Primary endpoint) | Week 6 (Drug washout) | |
| Amantadine | 17.3 | 17.1 |
| Placebo | 18.7 | 17.8 |
"Measure of neurobehavioral function and clinical change for individuals with severe alterations of consciousness.~Minimum score= 0; Maximum score= 23 (Higher scores are indicative of a higher-level of neurobehavioral function)." (NCT00970944)
Timeframe: Week 4 (primary endpoint); Week 6 (post-washout)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 4 (Primary endpoint) | Week 6 (Post-washout) | |
| Amantadine | 15.8 | 15.7 |
| Placebo | 14.2 | 15.1 |
18 reviews available for amantadine and Brain Injuries
| Article | Year |
|---|---|
Pharmacology in Treatment of Patients with Disorders of Consciousness.
Topics: Amantadine; Brain Injuries; Consciousness; Consciousness Disorders; Humans; Randomized Controlled Tr | 2024 |
Amantadine and memantine: a comprehensive review for acquired brain injury.
Topics: Amantadine; Brain Injuries; Humans; Memantine; Neuronal Plasticity; Off-Label Use; Recovery of Funct | 2020 |
Therapeutic options to enhance coma arousal after traumatic brain injury: state of the art of current treatments to improve coma recovery.
Topics: Amantadine; Arousal; Brain Injuries; Cell Transplantation; Central Nervous System Stimulants; Coma; | 2014 |
Facilitation of functional independence after neurotrauma: strategies for increasing physiologic readiness.
Topics: Amantadine; Analgesia; Brain Injuries; Dehydration; Dietary Supplements; Dopamine Agents; Frontal Lo | 2014 |
Amantadine for patients with severe traumatic brain injury: a critically appraised topic.
Topics: Adolescent; Amantadine; Analgesics, Non-Narcotic; Brain Injuries; Double-Blind Method; Female; Human | 2015 |
Care management of the agitation or aggressiveness crisis in patients with TBI. Systematic review of the literature and practice recommendations.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anti-Anxiety Agents; Anticonvulsants; Antipsych | 2016 |
Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice.
Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antidepressive Agents; Antipsychotic Agent | 2016 |
Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: a meta-analysis.
Topics: Adult; Amantadine; Behavior; Brain Injuries; Cognition Disorders; Controlled Clinical Trials as Topi | 2009 |
Acute management of acquired brain injury Part III: an evidence-based review of interventions used to promote arousal from coma.
Topics: Amantadine; Arousal; Brain Injuries; Bromocriptine; Coma, Post-Head Injury; Dopamine Agonists; Evide | 2010 |
Medical therapies for concussion.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Athletic Injuries; Brain Concussion; Bra | 2011 |
Pharmacological management for agitation and aggression in people with acquired brain injury.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anxiety; Brain Injuries; Humans; Methylphenidat | 2003 |
Improved neurological function after Amantadine treatment in two patients with brain injury.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Brain Injuries; Dopamine Agents; Female; Humans; Treatme | 2005 |
Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury.
Topics: Amantadine; Animals; Brain Injuries; Bromocriptine; Cognition Disorders; Dextroamphetamine; Humans; | 2005 |
Pharmacological management for agitation and aggression in people with acquired brain injury.
Topics: Adrenergic beta-Antagonists; Aggression; Amantadine; Anxiety; Brain Injuries; Humans; Methylphenidat | 2006 |
Amantadine treatment following traumatic brain injury in children.
Topics: Amantadine; Brain Injuries; Child; Cognition; Dopamine Agents; Female; Humans; Male; Treatment Outco | 2007 |
Amantadine enhancement of arousal and cognition after traumatic brain injury.
Topics: Amantadine; Arousal; Brain Injuries; Cognition; Humans; Recovery of Function; Time Factors | 2008 |
Possible applications for dopaminergic agents following traumatic brain injury: part 2.
Topics: Amantadine; Benzophenones; Benzothiazoles; Brain Injuries; Catechols; Dopamine Agents; Humans; Indol | 2001 |
Amantadine: a new clinical profile for traumatic brain injury.
Topics: Amantadine; Brain Injuries; Humans | 1989 |
Amantadine: a new clinical profile for traumatic brain injury.
Topics: Amantadine; Brain Injuries; Humans | 1989 |
Amantadine: a new clinical profile for traumatic brain injury.
Topics: Amantadine; Brain Injuries; Humans | 1989 |
Amantadine: a new clinical profile for traumatic brain injury.
Topics: Amantadine; Brain Injuries; Humans | 1989 |
12 trials available for amantadine and Brain Injuries
| Article | Year |
|---|---|
Amantadine for NeuroenhaNcement in acutE patients Study - a protocol for a prospective pilot proof of concept phase IIb study in intensive and intermediate care unit patients (ANNES).
Topics: Adult; Amantadine; Brain Injuries; Brain Injuries, Traumatic; Clinical Trials, Phase II as Topic; Co | 2023 |
Efficacy and safety of amantadine as a treatment for apathy after brain injury: Two single-case experimental design studies.
Topics: Adult; Amantadine; Apathy; Brain Injuries; Double-Blind Method; Executive Function; Humans | 2022 |
A placebo-controlled randomized clinical trial of amantadine hydrochloride for evaluating the functional improvement of patients following severe acute traumatic brain injury.
Topics: Amantadine; Brain Injuries; Brain Injuries, Traumatic; Dopamine; Dopamine Agents; Humans; Treatment | 2023 |
Medical complications during inpatient rehabilitation among patients with traumatic disorders of consciousness.
Topics: Adolescent; Adult; Aged; Amantadine; Brain Injuries; Consciousness Disorders; Dopamine Agents; Dose- | 2013 |
Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study.
Topics: Adult; Amantadine; Brain Injuries; Dopamine Agents; Double-Blind Method; Female; Humans; Irritable M | 2015 |
Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study.
Topics: Adolescent; Age Factors; Amantadine; Brain Injuries; Child; Child, Preschool; Consciousness Disorder | 2009 |
Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique.
Topics: Adolescent; Amantadine; Brain Injuries; Child; Consciousness; Consciousness Disorders; Cross-Over St | 2010 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Placebo-controlled trial of amantadine for severe traumatic brain injury.
Topics: Adult; Amantadine; Brain Injuries; Coma, Post-Head Injury; Disability Evaluation; Dopamine Agents; F | 2012 |
Dopamine agonist therapy in low-response children following traumatic brain injury.
Topics: Adolescent; Adult; Amantadine; Benzothiazoles; Brain Injuries; Child; Disability Evaluation; Dopamin | 2006 |
[Results of clinical trials of the antispasmodic agent memantine].
Topics: Aged; Amantadine; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; | 1982 |
Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study.
Topics: Adult; Amantadine; Analysis of Variance; Brain Injuries; Cognition; Confounding Factors, Epidemiolog | 1999 |
Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Amantadine; Axons; Brain Injuries; Cross-Over Studies; | 2002 |
38 other studies available for amantadine and Brain Injuries
| Article | Year |
|---|---|
Does amantadine maintain function in long-established brain injury? A single case experimental design.
Topics: Amantadine; Brain Injuries; Cognition; Consciousness; Humans; Single-Case Studies as Topic | 2021 |
Amantadine treatment is associated with improved consciousness in patients with non-traumatic brain injury.
Topics: Amantadine; Brain Injuries; Brain Ischemia; Consciousness; Delirium; Glasgow Coma Scale; Humans; Sei | 2022 |
Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study.
Topics: Amantadine; Amino Acids; Brain Injuries; Case-Control Studies; Consciousness Disorders; Female; Huma | 2020 |
Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study.
Topics: Amantadine; Amino Acids; Brain Injuries; Case-Control Studies; Consciousness Disorders; Female; Huma | 2020 |
Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study.
Topics: Amantadine; Amino Acids; Brain Injuries; Case-Control Studies; Consciousness Disorders; Female; Huma | 2020 |
Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study.
Topics: Amantadine; Amino Acids; Brain Injuries; Case-Control Studies; Consciousness Disorders; Female; Huma | 2020 |
Amantadine improves cognitive outcome and increases neuronal survival after fluid percussion traumatic brain injury in rats.
Topics: Amantadine; Analysis of Variance; Animals; Body Weight; Brain Injuries; CA2 Region, Hippocampal; CA3 | 2014 |
Amantadine ameliorates dopamine-releasing deficits and behavioral deficits in rats after fluid percussion injury.
Topics: Amantadine; Animals; Brain Injuries; Cognition; Corpus Striatum; Dopamine; Dopamine Agents; Drug Eva | 2014 |
Amantadine preserves dopamine level and attenuates depression-like behavior induced by traumatic brain injury in rats.
Topics: Amantadine; Animals; Antidepressive Agents; Apoptosis; Brain Injuries; Corpus Striatum; Depression; | 2015 |
Under arrest: the use of amantadine for treatment-refractory mood lability and aggression in a patient with traumatic brain injury.
Topics: Aggression; Amantadine; Brain Injuries; Criminals; Dopamine Agents; Humans; Male; Middle Aged; Mood | 2015 |
Preserving brain function in a comatose patient with septic hyperpyrexia (41.6 °C): a case report.
Topics: Adult; Amantadine; Anticonvulsants; Brain; Brain Injuries; Cognition Disorders; Coma; Dopamine Agent | 2017 |
Effect of amantadine sulphate on intracerebral hemorrhage-induced brain injury in rats.
Topics: Amantadine; Animals; Brain Edema; Brain Injuries; Cerebral Hemorrhage; Collagenases; Disease Models, | 2008 |
Effect of amantadine on the sleep-wake cycle of an inpatient with brain injury.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Brain Injuries; Dopamine Agents; Drug Admini | 2009 |
The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury.
Topics: Amantadine; Animals; Blotting, Western; Brain Injuries; Corpus Striatum; Dopamine Agents; Dopamine a | 2011 |
[Clinical and electroencephalographic effects of amantadine sulfate (PK-Merz) on consciousness disorders due to the severe traumatic brain injury].
Topics: Adolescent; Adult; Amantadine; Brain Injuries; Consciousness Disorders; Electroencephalography; Huma | 2011 |
Amantadine for severe traumatic brain injury.
Topics: Amantadine; Brain Injuries; Coma, Post-Head Injury; Dopamine Agents; Female; Humans; Male | 2012 |
Amantadine for severe traumatic brain injury.
Topics: Amantadine; Brain Injuries; Coma, Post-Head Injury; Dopamine Agents; Female; Humans; Male | 2012 |
Risperidone treatment of motor restlessness following anoxic brain injury.
Topics: Adolescent; Amantadine; Brain Injuries; Dopamine Agents; Drug Therapy, Combination; Humans; Hypoxia, | 2003 |
The use of dopamine enhancing medications with children in low response states following brain injury.
Topics: Adolescent; Adult; Amantadine; Arousal; Awareness; Benzothiazoles; Brain Injuries; Bromocriptine; Ch | 2003 |
Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study.
Topics: Adolescent; Amantadine; Brain Injuries; Child; Cognition; Dopamine Agents; Female; Humans; Male; Ret | 2004 |
Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy.
Topics: Adult; Amantadine; Brain; Brain Injuries; Cognition Disorders; Demyelinating Diseases; Diazepam; Dop | 2004 |
Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: A multicenter study.
Topics: Adult; Aged; Amantadine; Brain Injuries; Dantrolene; Data Collection; Disability Evaluation; Dopamin | 2005 |
Amantadine for traumatic brain injury: does it improve cognition and reduce agitation?
Topics: Administration, Oral; Adolescent; Adult; Aged; Amantadine; Brain Injuries; Cognition Disorders; Huma | 2005 |
Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amantadine; Brain Injuries; Cohort Studies; Coma, Post-H | 2005 |
Treatments to enhance recovery from the vegetative and minimally conscious states: ethical issues surrounding efficacy studies.
Topics: Amantadine; Brain Injuries; Caregivers; Decision Making; Ethics, Research; Humans; Multicenter Studi | 2007 |
Psychiatric sequelae of traumatic brain injury: a case report.
Topics: Adult; Amantadine; Brain Injuries; Clinical Protocols; Cognition Disorders; Cognitive Behavioral The | 2007 |
Pharmaceuticals for poststroke and brain injury rehabilitation.
Topics: Amantadine; Aphasia, Broca; Brain Injuries; Dopamine Agents; Humans; Methylphenidate; Persistent Veg | 2007 |
Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury.
Topics: Amantadine; Animals; Antidepressive Agents; Antipsychotic Agents; Brain Injuries; Cognition; Cogniti | 2008 |
Case vignettes of movement disorders.
Topics: Adult; Amantadine; Brain Injuries; Clonazepam; Diagnosis, Differential; Dystonia; Female; Haloperido | 1983 |
Amantadine treatment of a patient with anoxic brain injury.
Topics: Activities of Daily Living; Adolescent; Amantadine; Antiparkinson Agents; Brain Damage, Chronic; Bra | 1995 |
Unexpected amantadine intoxication in the death of a trauma patient.
Topics: Adult; Amantadine; Brain Injuries; Fatal Outcome; Female; Humans; Renal Insufficiency; Wounds and In | 1995 |
Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review.
Topics: Adult; Amantadine; Brain Injuries; Cognition Disorders; Dopamine Agents; Female; Frontal Lobe; Human | 1997 |
The combined use of amantadine and l-dopa/carbidopa in the treatment of chronic brain injury.
Topics: Amantadine; Behavior; Brain Injuries; Carbidopa; Chronic Disease; Cognition; Drug Therapy, Combinati | 1997 |
Amantadine: a potential treatment for the minimally conscious state.
Topics: Adult; Amantadine; Brain Injuries; Coma; Consciousness; Dopamine Agents; Dose-Response Relationship, | 1998 |
Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation.
Topics: Accidental Falls; Adult; Akathisia, Drug-Induced; Amantadine; Brain Injuries; Bromocriptine; Dopamin | 1999 |
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
Topics: Adolescent; Amantadine; Brain Injuries; Dopamine Agents; Dopamine Antagonists; Fever; Haloperidol; H | 1999 |
Early polyneuropharmacologic intervention in brain injury agitation.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Brain Injuries; Dextroamphetamine; Drug Adminis | 2002 |
[Amantadine in cognitive failure in patients with traumatic head injuries].
Topics: Adult; Amantadine; Attention; Brain Injuries; Cognition Disorders; Humans; Male; Middle Aged | 1992 |
Amantadine hydrochloride.
Topics: Amantadine; Brain Damage, Chronic; Brain Injuries; Humans; Neuropsychological Tests | 1991 |
[Results obtained with L-DOPA and amantadine in the treatment of patients with disorders of consciousness and of the vigilant state].
Topics: Adult; Aged; Amantadine; Attention; Brain Diseases; Brain Injuries; Brain Neoplasms; Cognition Disor | 1973 |
[On the therapeutic use of amantadine hydrochloride in non-parkinsonian hyperkinetic syndromes].
Topics: Adult; Amantadine; Athetosis; Brain Diseases; Brain Injuries; Cerebrovascular Disorders; Child; Chor | 1971 |